Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Quantidex NGS RNA Lung Cancer Kit

Asuragen has launched the QuantideX NGS RNA Lung Cancer Kit, a next-generation sequencing panel that analyzes known gene fusions, 3' and 5' imbalance markers, exon skipping events, and mRNA expression levels in non-small cell lung cancer samples. The kit is optimized for use with low-quality samples and low input samples, including from formalin-fixed paraffin-embedded and fine needle aspirations. It has also been designed to work with Asuragen's Sample-Aware bioinformatics software. According to the company, the panel can detect fusions and splice variants at 5 percent cell fraction and 1 percent cell fraction, respectively. 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more